The year-long impasse over regulating marketing of fixed dose combinations in the market between the industry and the authorities is being finally settled after a fruitful meeting between the DCGI Dr Surinder Singh and the pharma associations.
A consensus has been reached in the case of 138 combination drugs. At the meeting, described by the industry as one of the best ever with the authorities, it was agreed that 138 combinations out of the total 294 FDCs will be withdrawn from the market. The remaining 156 FDCs will be examined based on the scientific data and a final decision will be taken in course of time, sources said.
The details can be read here.
No comments:
Post a Comment